The US Food and Drug Administration has approved a new option for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
After clinical trials demonstrated a superior overall survival compared with standard care, the US Food and Drug Administration granted full approval to Blincyto.
